Association of the interleukin-22 genetic polymorphisms with ulcerative colitis

Diagnostic Pathology

Ying Zou⁴  Zheng Wan⁴  Shi Xue Dai²  Zhu Guo Wu³  Xue Bao Zheng¹  Hong Gang Chi¹ 

[1] Department of Traditional Chinese Medicine, The Second Clinical Medical College, Guangdong Medical College, 1 Xincheng Road, Songshan LakeSci.&Tech, Industry Park, Dongguan 523808, Guangdong, China;Emergency Department of Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;The Second Clinical Medical College, Guangdong Medical College, Dongguan 523808, China;Sino-American Cancer Research Institute, Guangdong Medical College, Dongguan 523808, China

关键词: Case¿control study;    Ulcerative colitis;    Gene polymorphism;    Interleukin-22;   

Others  :  1149523
DOI  :  10.1186/s13000-014-0183-y

 received in 2014-08-08, accepted in 2014-09-07,  发布年份 2014

【 摘 要 】

Background

Interleukin-22 (IL-22) is a member of the IL-10 family of anti-inflammatory cytokines that mediates epithelial immunity. IL-22 expression was found to be increased in patients with ulcerative colitis (UC). Whether genetic polymorphisms of IL-22 also influence UC risk is still unknown. The purpose of this study was to investigate the association between the IL-22 gene polymorphisms (?429 C/T, +1046 T/A and +1995 A/C) and the risk of UC in Chinese Han patients.

Methods

This hospital-based case¿control study comprised 180 patients with UC and 180 age- and gender-matched controls. Genotypes of 3 common polymorphisms of the IL-22 gene were determined by fluorogenic 5? exonuclease assays (TaqMan).

Results

Patients with UC had a significantly higher frequency of IL-22 ?429 TT genotype [odds ratio (OR) =2.43, 95% confidence interval (CI)?=?1.35, 4.37; P?=?0.003] and ?429 T allele (OR =1.54, 95% CI?=?1.14, 2.07; P?=?0.004) than controls. The findings are still emphatic by the Bonferroni correction. The IL-22?+1046 T/A and IL-22?+1995 A/C gene polymorphisms were not associated with a risk of UC. When stratifying by clinical type, location and disease severity of UC, no significant differences were found in any groups.

Conclusion

This is the first study to provide evidence for an association of IL-22 ?429 C/T gene polymorphisms with UC risk. Additional well-designed large studies were required for the validation of our results.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_183 webcite

【 授权许可】

   
2014 Chi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Tyler AD, Milgrom R, Stempak JM, Xu W, Brumell JH, Muise AM, Sehgal R, Cohen Z, Koltun W, Shen B, Silverberg MS: The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut 2013, 62:1433-1439.
• [2]Danese S, Fiocchi C: Ulcerative colitis. N Engl J Med 2011, 365:1713-1725.
• [3]Jess T, Rungoe C, Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012, 10:639-645.
• [4]Sartor RB: Mechanisms of disease: pathogenesis of Crohn¿s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
• [5]Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
• [6]Beaudoin M, Goyette P, Boucher G, Lo KS, Rivas MA, Stevens C, Alikashani A, Ladouceur M, Ellinghaus D, Torkvist L, Goel G, Lagacé C, Annese V, Bitton A, Begun J, Brant SR, Bresso F, Cho JH, Duerr RH, Halfvarson J, McGovern DP, Radford-Smith G, Schreiber S, Schumm PL, Sharma Y, Silverberg MS, Weersma RK, et al.: Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with Ulcerative colitis. Plos Genet 2013, 9:e1003723.
• [7]Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, et al.: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252.
• [8]Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y: Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005, 129:969-984.
• [9]Wolk K, Sabat R: Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006, 17:367-380.
• [10]Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
• [11]Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174:3695-3702.
• [12]Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA: Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
• [13]Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, Shi RH: Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol 2013, 19:2638-2649.
• [14]Yamamoto-Furusho JK, Miranda-Perez E, Fonseca-Camarillo G, Sanchez-Munoz F, Dominguez-Lopez A, Barreto-Zuniga R: Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis. Inflamm Bowel Dis 2010, 16:1823.
• [15]Hennig BJ, Frodsham AJ, Hellier S, Knapp S, Yee LJ, Wright M, Zhang L, Thomas HC, Thursz M, Hill AV: Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 2007, 27:1134-1143.
• [16]Endam LM, Bosse Y, Filali-Mouhim A, Cormier C, Boisvert P, Boulet LP, Hudson TJ, Desrosiers M: Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis. Otolaryngol Head Neck Surg 2009, 140:741-747.
• [17]Weger W, Hofer A, Wolf P, El-Shabrawi Y, Renner W, Kerl H, Salmhofer W: Common polymorphisms in the interleukin-22 gene are not associated with chronic plaque psoriasis. Exp Dermatol 2009, 18:796-798.
• [18]Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L: Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010, 21:1165-1170.
• [19]Ding GG, Zhang GL, Chen XC, Zhang MX, Yang L, Wang Z: A study on the relationship between single nucleotide polymorphisms of interleukin-22 and susceptibility to pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2012, 35:596-600.
• [20]Musolino C, Allegra A, Ferraro M, Aguennouz M, Russo S, Alonci A, Saitta S, Gangemi S: Involvement of T2677T multidrug resistance gene polymorphism in Interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients. Acta Oncol 2012, 51:406-408.
• [21]Eun YG, Shin IH, Lee YC, Shin SY, Kim SK, Chung JH, Kwon KH: Interleukin 22 polymorphisms and papillary thyroid cancer. J Endocrinol Invest 2013, 36:584-587.
• [22]Suh JS, Cho SH, Chung JH, Moon A, Park YK, Cho BS: A polymorphism of interleukin-22 receptor alpha-1 is associated with the development of childhood IgA nephropathy. J Interferon Cytokine Res 2013, 33:571-577.
• [23]Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
• [24]Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
• [25]Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2:1041-1048.
• [26]Langholz E, Munkholm P, Davidsen M, Binder V: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994, 107:3-11.
• [27]Sivaram G, Tiwari SK, Bardia A, Anjum F, Vishnupriya S, Habeeb A, Khan AA: Macrophage migration inhibitory factor, Toll-like receptor 4, and CD14 polymorphisms with altered expression levels in patients with ulcerative colitis. Hum Immunol 2012, 73:201-205.
• [28]Mo JS, Na KS, Yu JI, Chae SC: Identification of the polymorphisms in IFITM1 gene and their association in a Korean population with ulcerative colitis. Immunol Lett 2013, 156:118-122.
• [29]Yamamoto-Furusho JK, De-Leon-Rendon JL, de la Torre MG, Alvarez-Leon E, Vargas-Alarcon G: Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis. Immunol Lett 2013, 149:50-53.
• [30]Shiotani A, Kusunoki H, Kimura Y, Ishii M, Imamura H, Tarumi K, Manabe N, Kamada T, Hata J, Haruma K: S100A expression and interleukin-10 polymorphisms are associated with Ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 2013, 58:2314-2323.
• [31]Yu JI, Kang IH, Seo GS, Choi SC, Yun KJ, Chae SC: Promoter polymorphism of the EED gene is associated with the susceptibility to Ulcerative colitis. Dig Dis Sci 2012, 57:1537-1543.
• [32]Zhang JX, He JH, Wang J, Song J, Lei HB, Wang J, Dong WG: Associations between PTPN2 polymorphisms and susceptibility to ulcerative colitis and Crohn¿s disease: a meta-analysis. Inflamm Res 2014, 63:71-79.
• [33]Xue LN, Xu KQ, Zhang W, Wang Q, Wu J, Wang XY: Associations between vitamin D receptor polymorphisms and susceptibility to Ulcerative colitis and Crohn¿s disease: a meta-analysis. Inflamm Bowel Dis 2013, 19:54-60.
• [34]Wang B, Zhao XP, Fan YC, Zhang JJ, Zhao J, Wang K: IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. Antiviral Res 2013, 97:285-292.
• [35]Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, Wolters VM, Bandsma RH, Mouzaki M, Zachos M, Langer JC, Cutz E, Benseler SM, Roifman CM, Silverberg MS, Griffiths AM, Snapper SB, Muise AM: IL-10R polymorphisms are associated with very-early-onset Ulcerative colitis. Inflamm Bowel Dis 2013, 19:115-123.
• [36]Bardia A, Tiwari SK, Gunisetty S, Anjum F, Nallari P, Habeeb MA, Khan AA: Functional polymorphisms in XRCC-1 and APE-1 contribute to increased apoptosis and risk of ulcerative colitis. Inflamm Res 2012, 61:359-365.
• [37]Yamamoto-Furusho JK, Santiago-Hernandez JJ, Perez-Hernandez N, Ramirez-Fuentes S, Fragoso JM, Vargas-Alarcon G: Interleukin 1 beta (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with Ulcerative colitis. J Clin Gastroenterol 2011, 45:531-535.
• [38]Yamamoto-Furusho JK, Alvarez-Leon E, Fragoso JM, Gozalishvilli A, Vallejo M, Vargas-Alarcon G: Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. Hum Immunol 2011, 72:1029-1032.
• [39]Wolk K, Warszawska K, Hoeflich C, Witte E, Schneider-Burrus S, Witte K, Kunz S, Buss A, Roewert HJ, Krause M, Lukowsky A, Volk HD, Sterry W, Sabat R: Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011, 186:1228-1239.
• [40]Zhang L, Cheng Z, Liu W, Wu K: Expression of interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD 2013, 10:459-465.
• [41]Luo Z, Wang H, Sun Z, Luo W, Wu Y: Expression of IL-22, IL-22R and IL-23 in the peri-implant soft tissues of patients with peri-implantitis. Arch Oral Biol 2013, 58:523-529.
• [42]Cai T, Wang Q, Zhou Q, Wang C, Hou S, Qi J, Kijlstra A, Yang P: Increased expression of IL-22 is associated with disease activity in Behcet¿s disease. PLoS One 2013, 8:e59009.
• [43]Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M, Miyara M, Hie M, Piette JC, Frances C, Yssel H, Amoura Z, Gorochov G: Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 2012, 71:1227-1234.
• [44]Zhu J, Cao Y, Li K, Wang Z, Zuo P, Xiong W, Xu Y, Xiong S: Increased expression of aryl hydrocarbon receptor and interleukin 22 in patients with allergic asthma. Asian Pac J Allergy Immunol 2011, 29:266-272.